Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 4/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | PPARD | Q03181 | 1/20 | 0.51 |
| ▸ | ALB | P02768 | 1/20 | 0.49 |
| ▸ | UNG | P13051 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.40 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.38 |
| ▸ | ACSL6 | Q9UKU0 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17685826 | 0.90 | PPARA (0.60) | PLA2G2APPARAFFAR1PPARGPPARD | |
| SCHEMBL16012896 | 0.88 | PPARA (0.58) | PLA2G2APPARAFFAR1PPARGPPARD | |
| SCHEMBL2773374 | 0.82 | PLA2G2A (0.65) | PLA2G2ATP53TSHRPLA2G4BKMT2A | |
| SCHEMBL17685748 | 0.82 | PPARA (0.53) | PLA2G2APPARAFFAR1PPARGPPARD | |
| SCHEMBL17685848 | 0.81 | PPARA (0.52) | PPARAFFAR1PPARGPPARDALB | |
| SCHEMBL17685777 | 0.81 | PPARA (0.52) | PPARAFFAR1PPARGPPARDALB | |
| SCHEMBL17685824 | 0.80 | PPARA (0.51) | PLA2G2APPARAFFAR1PPARGPPARD | |
| SCHEMBL557573 | 0.78 | PLA2G2A (0.55) | PLA2G2APPARAFFAR1PPARGPPARD | |
| SCHEMBL20211823 | 0.78 | PPARA (0.58) | PPARAFFAR1PPARGPPARDALB | |
| SCHEMBL20211722 | 0.78 | PPARA (0.58) | PPARAFFAR1PPARGPPARDALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46170-E1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2016-10-04 | — | — | US | disclosed |
| EP-2256130-B1 | Novel insulin derivatives | NOVO NORDISK AS (DK) | 2013-09-25 | — | — | EP | disclosed |
| US-8476228-B2 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2013-07-02 | — | — | US | disclosed |
| EP-1846446-B1 | INSULIN DERIVATIVES | NOVO NORDISK AS (DK) | 2013-06-26 | — | — | EP | disclosed |
| US-20120035104-A1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2012-02-09 | — | — | US | disclosed |
| US-8067362-B2 | Antidiabetic agents; genetic engineered polypeptide; having a side chain attached alpha -amino group of the N-terminal amino acid of the B chain via an amide bond, with free carboxylic acid group, a fatty acid; soluble at physiological pH, prolonged profile of action; hypoglycemic agents | NOVO NORDISK AS (DK) | 2011-11-29 | — | — | US | disclosed |
| EP-2256130-A1 | Novel insulin derivatives | Novo Nordisk A/S (DK) | 2010-12-01 | — | — | EP | disclosed |
| US-20080076705-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2008-03-27 | — | — | US | disclosed |
| EP-1846446-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006082204-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035104-A1 | Insulin derivatives | IAPP, INSR, GPR119 | PLA2G2A 2377/4885PPARA 179/4885FFAR1 32/4885 |
| US-20080076705-A1 | Insulin Derivatives | IAPP, INSR, GPR119 | PLA2G2A 2219/4885PPARA 250/4885FFAR1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.